awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q42096514-C0C5B6B1-605C-4B95-9DDA-62B493F9DAEA
Q42096514-C0C5B6B1-605C-4B95-9DDA-62B493F9DAEA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42096514-C0C5B6B1-605C-4B95-9DDA-62B493F9DAEA
Is there still a place for docetaxel rechallenge in prostate cancer?
P2860
Q42096514-C0C5B6B1-605C-4B95-9DDA-62B493F9DAEA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q42096514-C0C5B6B1-605C-4B95-9DDA-62B493F9DAEA
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
c0154a06d4b5a58217a34b3afbc4483522f2c0ce
P2860
Rechallenge of docetaxel combined with epirubicin given on a weekly schedule in advanced castration-resistant prostate cancer patients previously exposed to docetaxel and abiraterone acetate: a single-institution experience.